Form 10-Q GALECTIN THERAPEUTICS For: Jun 30
Tweet
Share
E-mail
http://archive.fast-edgar.com/20140807/AI2LUQ2FZ22RVZZ2222C2ZXPB4DNZZ223262
Filed on: August 7, 2014
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NU E Power Corp. Files 2026 First Quarter Results
- OpenText to Create 400 Jobs with €105 Million Investment in Cork and Galway to Expand Agentic AI and Sovereign Cloud in Europe
- Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
